QCDx is creating novel diagnostics for personalized and early cancer detection based on a standard blood sample.
Every nucleated cell is analyzed and characterized to detect circulating tumor cells via multiple biomarkers selected based on the patient’s clinical history. QCDx provides the oncologist with quantitative, actionable information on treatment efficacy, development of resistance, recurrence monitoring and metastasis characterization. This will offer the patient an optimized therapeutic intervention to restrict and potentially halt tumor growth. QCDx proprietary, high resolution, fluorescence microscopy analyzes millions of cells fixed or ex vivo. Operation is fully automated using advanced image analysis and artificial intelligence. Clinical trial of the first QCDx test for breast cancer is scheduled to start in 3Q of 2018.
Contact: Triantafyllos (Fyl) Tafas PhD, CEO